The FDA/DIA Forum provides a venue to discuss important statistical issues associated with the development and review of therapeutic drugs and biologics. The meeting is intended to be an annual, open dialogue to discuss FDA's issues, initiatives and guidance – emphasizing the statistical and regulatory challenges.